MeiraGTx (MGTX) Stock Price, News & Analysis

Company Overview

MeiraGTx is a clinical-stage biotechnology company specializing in the development and commercialization of adeno-associated virus (AAV) gene therapies for rare diseases with high unmet medical need. Since its founding in 2014 as a spin-out from GlaxoSmithKline, the company has built a proprietary AAV platform designed to deliver therapeutic genes to target tissues with precision and durability. Its research and development efforts are focused on ophthalmology, central nervous system disorders, lysosomal storage diseases and oncology indications.

The company’s lead program, LUMEVOQ (AAV2-REP1), targets choroideremia, a rare inherited retinal degeneration, and has advanced through Phase II/III clinical studies. Additional programs leverage varying AAV serotypes and promoters to optimize tissue tropism, including candidates for X-linked retinitis pigmentosa, spinal muscular atrophy and hemophilia A. MeiraGTx also collaborates with academic institutions and biotech partners to expand its pipeline into new therapeutic areas and enhance manufacturing capabilities for clinical and commercial-scale AAV production.

Headquartered in London with a corporate presence in New York, MeiraGTx operates a fully integrated development and manufacturing infrastructure that spans discovery, preclinical research and regulatory engagement. The company has established GMP-compliant manufacturing suites in the United Kingdom and the United States to support its late-stage programs and prospective commercial launches. This integrated model aims to streamline process development and ensure timely supply of clinical material.

MeiraGTx is led by a management team and board of directors with extensive experience in gene therapy, regulatory affairs and biopharmaceutical commercialization. The leadership group combines expertise drawn from major pharmaceutical companies, academic research centers and specialized gene therapy organizations, positioning MeiraGTx to navigate the regulatory landscape and advance its pipeline toward potential regulatory approvals.

Key Stats

• Today's Range: $8.14 to $8.75
• 50-Day Range: $4.64 to $8.62
• 52-Week Range: $3.85 to $8.75
• Volume: 1.26 million shs
• Average Volume: 403,717 shs
• Market Capitalization: $692.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Buy

MeiraGTx Stock Analysis - MarketRank™

MeiraGTx scored higher than 89% of companies evaluated by MarketBeat, and ranked 125th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MeiraGTx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MeiraGTx are expected to grow in the coming year, from ($1.48) to $0.38 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MeiraGTx is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MeiraGTx is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MeiraGTx has a P/B Ratio of 9.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.94% of the float of MeiraGTx has been sold short.

Short Interest Ratio / Days to Cover

MeiraGTx has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in MeiraGTx has recently increased by 17.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MeiraGTx does not currently pay a dividend.

Dividend Growth

MeiraGTx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.54

Percentage of Shares Shorted

4.94% of the float of MeiraGTx has been sold short.

Short Interest Ratio / Days to Cover

MeiraGTx has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in MeiraGTx has recently increased by 17.25%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.39

News Sentiment

MeiraGTx has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for MeiraGTx this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for MGTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added MeiraGTx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $522,575.00 in company stock.

Percentage Held by Insiders

Only 7.50% of the stock of MeiraGTx is held by insiders.

Percentage Held by Institutions

67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MGTX Stock Analysis - Frequently Asked Questions

How have MGTX shares performed this year?

MeiraGTx's stock was trading at $6.09 at the beginning of the year. Since then, MGTX shares have increased by 41.5% and is now trading at $8.62.

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings PLC (NASDAQ:MGTX) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.13. The business had revenue of $1.93 million for the quarter, compared to analyst estimates of $4.44 million. MeiraGTx had a negative net margin of 484.90% and a negative trailing twelve-month return on equity of 241.05%.

When did MeiraGTx IPO?

MeiraGTx (MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

How do I buy shares of MeiraGTx?

Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MeiraGTx investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Moderna (MRNA).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGTX
• CIK: 1735438
• Web: www.meiragtx.com
• Phone: (646) 860-7985
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MeiraGTx: $24.00
• High Price Target: $35.00
• Low Price Target: $13.00
• Potential Upside/Downside: +178.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$147.79 million
• Net Margins: -484.90%
• Pretax Margin: -484.90%
• Return on Equity: -241.05%
• Return on Assets: -62.93%

Debt

• Debt-to-Equity Ratio: 2.34
• Current Ratio: 1.53
• Quick Ratio: 1.51

Sales & Book Value

• Annual Sales: $33.28 million
• Price / Sales: 20.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.87 per share
• Price / Book: 9.91

Miscellaneous

• Outstanding Shares: 80,360,000
• Free Float: 74,338,000
• Market Cap: $692.70 million
• Optionable: Optionable
• Beta: 1.24